Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

[1]  R. Larson.  Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? , 2003, Leukemia.

[2]  M. Caligiuri,et al.  Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. , 2002, Blood.

[3]  J. Doroshow,et al.  Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.

[4]  A. Burnett,et al.  Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial , 2001, British journal of haematology.

[5]  P. Sonneveld,et al.  MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. , 2001, Blood.

[6]  E. D. de Vries,et al.  P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  L. Doyle,et al.  Expression of breast cancer resistance protein in blast cells from patients with acute leukemia , 2000 .

[8]  R. Arceci,et al.  Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Sonneveld.  Multidrug resistance in haematological malignancies , 2000, Journal of internal medicine.

[10]  O. Legrand,et al.  Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. , 1999, Blood.

[11]  M. Baccarani,et al.  P‐glycoprotein, lung resistance‐related protein and multidrug resistance associated protein in de novo acute non‐lymphocytic leukaemias: biological and clinical implications , 1999, British journal of haematology.

[12]  B. Sikic,et al.  Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia , 1999, Cancer.

[13]  W. Hiddemann,et al.  Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison , 1998, Leukemia.

[14]  C. Klumb,et al.  Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide. , 1997, Journal of experimental & clinical cancer research : CR.

[15]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[16]  E. Bow,et al.  Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Willman.  Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). , 1996, Leukemia.

[18]  T. Grogan,et al.  Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. , 1996, Blood.

[19]  F. Appelbaum,et al.  Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. , 1995, Blood.

[20]  B. Sikic,et al.  Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Sonneveld,et al.  Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). , 1994, Leukemia.

[22]  P. Sonneveld,et al.  Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. , 1993, Blood.

[23]  W. Dalton,et al.  Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Delmer,et al.  Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). , 1993, Leukemia.

[25]  S. Srimatkandada,et al.  Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. , 1993, The Journal of clinical investigation.

[26]  M. Slovak,et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[27]  W. Hiddemann,et al.  High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. , 1993, Leukemia & lymphoma.

[28]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[29]  I. Roninson,et al.  Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. , 1992, Blood.

[30]  S. Zhao,et al.  Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. , 1992, Blood.

[31]  M. Sehested,et al.  Relationship of VP-16 to the Classical Multidrug Resistance Phenotype1 , 2006 .

[32]  I. Roninson,et al.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.

[33]  H. Garewal,et al.  Expression of the multidrug resistance gene product (P‐glycoprotein) in myelodysplasia is associated with a stem cell phenotype , 1991, British journal of haematology.

[34]  W. Hiddemann,et al.  High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. , 1991, Seminars in hematology.

[35]  R. L. Felsted,et al.  P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. , 1990, Molecular pharmacology.

[36]  P. Sonneveld,et al.  Overexpression of the MDRL gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin‐A , 1990, International journal of cancer.

[37]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  I. Pastan,et al.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[39]  I. Pastan,et al.  Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.

[40]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  I. Pastan,et al.  Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Gupta,et al.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. , 1986, The Journal of clinical investigation.

[43]  G. Curt,et al.  Drug resistance in cancer. , 1984, Cancer treatment reports.

[44]  T. Tsuruo,et al.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.

[45]  T. Skovsgaard.  Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. , 1978, Cancer research.

[46]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.